ACHL - Achilles Therapeutics PLC ADR - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ACHL is currently covered by 3 analysts with an average price target of $4.38. This is a potential upside of $3.02 (222.06%) from yesterday's end of day stock price of $1.36.

Achilles Therapeutics PLC ADR's activity chart (see below) currently has 8 price targets and 19 ratings on display. The stock rating distribution of ACHL is 83.33% BUY and 16.67% SELL.

Stock Analyst Price Targets - Review

Highest price target for ACHL is $6, Lowest price target is $2, average price target is $4.38.

Most recent stock forecast was given by JOSEPH CATANZARO from PIPER SANDLER on 05-Apr-2024. First documented stock forecast 26-Apr-2021.

Best performing analysts who are covering ACHL - Achilles Therapeutics PLC ADR:

Joseph Catanzaro Geulah Livshits Tazeen Ahmad Mark Breidenbach

Currently out of the existing stock ratings of ACHL, 5 are a BUY (83.33%), 1 are a SELL (16.67%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$2

$0.87 (76.99%)

9 months 30 days ago
(05-Apr-2024)

0/5 (0%)

$1.1 (122.22%)

Buy

$6

$4.87 (430.97%)

9 months 30 days ago
(05-Apr-2024)

0/2 (0%)

$5.1 (566.67%)

Sell

$0.5

$-0.63 (-55.75%)

$20

1 years 1 months 21 days ago
(14-Dec-2023)

0/2 (0%)

$-0.36 (-41.86%)

Buy

2 years 1 months 29 days ago
(06-Dec-2022)

0/1 (0%)

$6.25 (37.31%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ACHL (Achilles Therapeutics PLC ADR) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on ACHL (Achilles Therapeutics PLC ADR) with a proven track record?

JOSEPH CATANZARO

Which analyst has the current lower performing score on ACHL (Achilles Therapeutics PLC ADR) with a proven track record?

MARK BREIDENBACH

Which analyst has the most public recommendations on ACHL (Achilles Therapeutics PLC ADR)?

Joseph Catanzaro works at PIPER SANDLER and has 9 price targets and 7 ratings on ACHL

Which analyst is the currently most bullish on ACHL (Achilles Therapeutics PLC ADR)?

Geulah Livshits with highest potential upside - $4.87

Which analyst is the currently most reserved on ACHL (Achilles Therapeutics PLC ADR)?

Tazeen Ahmad with lowest potential downside - -$0.63

Achilles Therapeutics PLC ADR in the News

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 –...

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?